Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOCODIHF: Empagliflozin in Type 2 Diabetes and Ischemic Heart Failure
2015-005715-32Phase 4Terminated
- Sponsor
- Karolinska Institutet
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of empagliflozin in type 2 diabetes mellitus (T2DM) and heart failure (HF), sponsored by Karolinska Institutet. Primary endpoint: Improvement in myocardial function, structure and coronary flow reserve. Started Feb 2016; status: terminated.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)heart failure (HF)
Beyond the preview
Go deeper on 2015-005715-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005715-32.